Business Wire

H.I.G. WhiteHorse Invests in Savio Group

30.6.2017 13:59 | Business Wire

Del

H.I.G. WhiteHorse, a credit affiliate of global investment firm H.I.G. Capital, has completed, alongside Tikehau Capital, an investment of €85 million in Notes issued by Savio Group, controlled by Alpha Private Equity. Based in Pordenone, Italy, Savio Group is a global leader in production of machinery and quality control systems for the textile industry.

Guido Lorenzi, Director at H.I.G. WhiteHorse in Milan, said: “This transaction reaffirms H.I.G. WhiteHorse’s commitment to invest in Italy, supporting leading companies and its ability to originate proprietary transactions. We will support the next stage of development of the Company. We continue to see Italy as a highly attractive market.”

About Savio Group

Based in Pordenone, Italy, Savio Group is the world leader in the yarn finishing machine sector, operating worldwide in the design, manufacturing and marketing of automatic winders, quality control devices, rotor spinning frames and electronic boards, with factories in Italy, China, India, Belgium, Germany and Switzerland.

Established over one century ago, Savio evolved through the years through intense Research & Development, highest manufacturing flexibility and high quality standards. Its global footprint, flexibility and production excellence are Savio's principal strategic assets, continuously building on and consolidating its leadership through time.

About Alpha Private Equity

Alpha is a leading mid-market firm operating in the continental European market, with a unique and differentiated approach that has delivered consistent, top quartile performance across economic cycles. Thanks to its reputation and extensive network of relationships, Alpha is able to invest predominantly in primary deals in family-owned businesses. Alpha has a highly experienced team of 32 individuals across 6 offices.

About H.I.G. WhiteHorse

H.I.G. WhiteHorse is the credit affiliate of H.I.G. Capital focused on providing flexible debt financing solutions to middle market companies in Europe and the United States. Operating a broad investment mandate, H.I.G. WhiteHorse provides unitranche, senior and subordinated debt capital for refinancings, growth capital, acquisitions, buyouts, and balance sheet recapitalizations. Credit facilities typically range from €10 million to €75 million for companies with revenues of €40 million or more. For more information, please refer to the WhiteHorse website at: www.higeurope.com/whitehorse.

About H.I.G. Capital

H.I.G. is a leading global private equity and alternative assets investment firm with more than €20 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Mexico City and Rio de Janeiro, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused/ value-added approach:

1. H.I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.

2. H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.

3. H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.

Since its founding in 1993, H.I.G. has invested in and managed more than 200 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of €28 billion. For more information, please refer to the H.I.G. website at www.higcapital.com.

* Based on total capital commitments managed by H.I.G. Capital and affiliates.

Contact information

H.I.G. WhiteHorse
Appu Mundassery
Managing Director
amundassery@higwhitehorse.com
or
Kenneth Borton
Managing Director
kborton@higwhitehorse.com
or
Guido Lorenzi
Director
glorenzi@higwhitehorse.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

XILAM Successfully Completes €15m Bond Issue on Euro PP Market27.7.2017 17:42Pressemelding

Regulatory News: Xilam (Paris:XIL) today announced the completion of its Euro PP bond issue. The €15 million private placement, repayable at maturity, was subscribed by the NOVI 2 fund managed by Idinvest Partners on behalf of institutional investors and by a European insurer. The bonds have a 6-year maturity, and will be issued in two tranches: The first tranche will be at a variable rate of 6-month EURIBOR* + 400 bp The second tranche will be at a fixed rate of 3.5%. Favourable terms were obtained for the issue with successive drawdown options (limited to 18 months), which will allow the company to optimise the cost of its debt according to its needs. Xilam was advised on the transaction by Euroland Corporate. “We are delighted to have successfully completed this financing transacti

SFL – First-Half 2017 Results27.7.2017 17:00Pressemelding

Regulatory News: The interim consolidated financial statements for the six months ended 30 June 2017 were approved by the Board of Directors of Société Foncière Lyonnaise (Paris:FLY) on 27 July 2017, at a meeting chaired by Juan-Jose Brugera. First-half business indicators were robust, thanks to the high portfolio occupancy rate, while the period also saw gains in the portfolio's appraisal value and the Company's net asset value. The auditors have completed their review of the interim financial statements. Consolidated data (€ millions)                

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®27.7.2017 13:00Pressemelding

Boehringer Ingelheim announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study. The goal of the study is to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40mg/0.8mL. This is the first study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate. The study will compare the pharmacokinetics and clinical outcomes between patients receiving Humira® continuously, versus those who switch repeatedly between Humira® and BI 695501, Boehringer Ingelheim’s adalimumab biosimilar candidate.1 The study will also assess safety, immunogenicity and efficacy.1 “We are pleased that the first patient has now been enrolled in VOLTAIRE-X, and look forward to continued recruitment and patient follow-up,” said Ivan Blanarik, Senior Vice President and Head of

Acxiom Launches Connected Spaces27.7.2017 12:30Pressemelding

Today, Acxiom® (Nasdaq: ACXM), in collaboration with Adobe, announced the launch of Connected Spaces, a global solution aimed at delivering more relevant omnichannel experiences to customers. Connected Spaces is designed to revolutionise customer experience and business returns for retail, travel and leisure locations such as airports, malls, sports stadiums, concert arenas and resorts. A pioneering example is Heathrow airport. Heathrow is able to deliver more relevant communications to customers in real-time as part of its overall engagement strategy and is already generating exceptional results including an increase in spend of 20-25 percent for engaged customers. Common to airports, malls and the like is a high footfall of consumers who intend to visit multiple concession, franchise, or subcontracted brands operating in their environments. This can translate to a relative

Watch BizWireTV: Helix Brings DNA Kits to the Public and Michael Kors Gets Ready to Buy Jimmy Choo27.7.2017 12:08Pressemelding

On the latest BizWireTV, catch the latest Quick Biz Hits. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170727005456/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire) Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Helix launches first online consumer marketplace for DNA-powered products that offer insights on ancestry, entertainment, family, fitness, health and nutrition. Watch BizWireTV to

European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals’ Investigational Therapy for the Treatment of Primary Hyperoxaluria27.7.2017 11:05Pressemelding

Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral enzyme therapeutics to patients with serious renal, urologic and orphan diseases, announced today that the European Commission has granted orphan drug designation to Allena’s investigational product ALLN-177, Bacillus subtilis oxalate decarboxylase, for the treatment of primary hyperoxaluria (PH). The orphan designation was granted to Allena Pharmaceuticals Ireland Limited, a subsidiary of Allena Pharmaceuticals, Inc. Allena’s lead compound ALLN-177, is being developed to treat patients with severe hyperoxaluria, a condition characterized by markedly elevated urinary oxalate excretion. PH, a type of severe hyperoxaluria, is a rare genetic disorder caused by endogenous overproduction of oxalate by the liver that can result in kidney stone disease, kidney

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom